IntraLase and Tissue Banks International Announce Installation of Femtosecond Laser at The National Eye Bank Center; TBI Will Be First to Use Laser for Large-Scale Preparation of Corneal Allografts.
IRVINE, Calif. -- IntraLase Corp. (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ILSE ILSE International Life Saving Europe
ILSE Intermediate Level Support Equipment
ILSE Iterative Least-Squares Estimator ) and Tissue Banks International are pleased to announce the execution of an agreement to install an IntraLase FS laser for the preparation of corneal corneal
pertaining to the cornea. See also keratitis, keratopathy.
includes microcornea, coloboma, megalocornea, dermoid, congenital opacity.
corneal black body
see corneal sequestrum (below). allografts allografts (al´graf´ts),
n.pl the transplantation of tissue between genetically nonidentical individuals of the same species. at The National Eye Bank Center, TBI's new state-of-the-art facility in Memphis, Tenn. TBI TBI 1. Thyroxine-binding index 2. Total body irradiation will be the first large-scale eye bank organization to use the IntraLase FS (femtosecond) laser for preparation of corneal allografts for transplant.
The laser will be used to prepare allografts for posterior lamellar lamellar /la·mel·lar/ (lah-mel´ar)
1. pertaining to or resembling lamellae.
2. lamellated (1).
pertaining to or emanating from lamella. , anterior lamellar, and full thickness corneal transplants. Initial clinical work suggests that allografts prepared with IntraLase's femtosecond laser are stronger than those prepared with traditional penetrating keratoplasty keratoplasty /ker·a·to·plas·ty/ (ker´ah-to-plas?te) plastic surgery of the cornea; corneal transplantation.
optic keratoplasty , with less induction of astigmatism astigmatism (əstĭg`mətĭz'əm), type of faulty vision caused by a nonuniform curvature in the refractive surfaces—usually the cornea, less frequently the lens—of the eye. .
"We are very excited about this new application for the IntraLase femtosecond laser and delighted to see it utilized by TBI at The National Eye Bank Center," said Bernard Haffey, executive vice president and chief commercial officer of IntraLase. "Based on initial results with other donor bank users, we believe that corneal surgeons will be pleased with the advantages for their patients provided by a precisely prepared corneal allograft allograft: see transplantation, medical. ," Haffey explained.
"TBI is proud to be on the cutting edge of eye-banking with the installation of the femtosecond laser," said Gerald Cole, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Tissue Banks International. "The preparation of precision-cut corneal allografts was one of the primary reasons we established The National Eye Bank Center. The efficiencies of our centralized processing and the transportation advantages of our Memphis location mean we can provide surgeons with their requested allografts quickly."
Beyond the installation of the femtosecond laser, IntraLase and Tissue Banks International have plans to collaborate on future applications and improvements as part of both TBI's and IntraLase's commitment to maximizing the benefits of this exciting technology.
The femtosecond laser is an extremely precise laser that received FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. clearance for the preparation of corneal allografts on Sept. 7, 2005. The ultrashort pulses the laser uses to cut tissue are too brief to transfer heat or shock, which means that cutting occurs with virtually no damage to surrounding material.
The National Eye Bank Center is a state-of-the-art facility designed to centralize the screening, evaluation, and shipping of eye tissue for sight-restoring corneal transplant surgery. The first such Center in the world, the multi-million dollar project will offer surgeons and their patients the largest concentration of ocular tissue and pre-cut grafts for ocular surgery. The Center ensures tissue's safety, quality, and rapid and efficient distribution to surgeons and researchers in the U.S. and overseas.
IntraLase designs, develops and manufactures an ultra-fast laser, related software and disposable devices used to create a corneal flap, the first step in LASIK LASIK laser-assisted in-situ keratomileusis.
Eye surgery in which the surface of the cornea is reshaped using a laser, performed to correct certain refractive disorders such as myopia. surgery for the correction of vision. The company's products improve the safety, precision and visual results of LASIK procedures by providing a computer-controlled laser solution in place of the hand-held mechanical, metal-bladed microkeratome traditionally used to create corneal flaps. IntraLase lasers are also used in surgical approaches to the treatment of diseased corneas. The company's lasers and disposable per procedure patient interfaces are presently marketed throughout the United States and 21 other countries. IntraLase has headquarters and manufactures its products in Irvine. For additional information, visit the company's Web site: www.intralase.com.
Non-profit TBI/Tissue Banks International, founded as a single eye bank in 1962, today is a far-reaching network of associated eye and tissue banks throughout the United States and around the world. Providing nearly 10,000 corneas annually, TBI is the largest singular provider of ocular tissue in the world. For additional information about TBI and The National Eye Bank Center, visit TBI's Web site: www.tbionline.org.
Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," or "may." Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Those risks and uncertainties include, but are not limited to: the degree of continued acceptance of LASIK surgery; potential complications revealed by long-term follow up; the extent of adoption of our product offering by LASIK surgeons; general economic conditions; changes in federal tax laws governing the ability of potential LASIK patients to use pre-tax dollars to pay for LASIK surgery; the scope of government regulation applicable to our products; patients' willingness to pay Willingness to pay (WTP) generally refers to the value of a good to a person as what they are willing to pay, sacrifice or exchange for it. See also
Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on form 10-Q Form 10-Q
See 10-Q. for the period ending June 30, 2005, as filed with the Securities and Exchange Commission on Aug. 10, 2005.
These forward-looking statements are made only as of the date of this press release, and the company assumes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.